Progress and Challenges in Pulmonary Fibrosis (IPF) and Nebulized Tyvaso Trials
United Therapeutics is on the cusp of reporting results from the TETON 2 study in September, evaluating nebulized Tyvaso in IPF patients outside the U.S. and Canada.
TETON 2 involves 597 patients, with primary endpoint being change in FVC at 52 weeks.
The company aims to support a regulatory filing with the FDA for IPF indication in 2027 if results are successful.
The study design includes efforts to reduce variability in FVC measurements through central reading and standardized procedures.
ACADIA's Pipeline Milestones and Upcoming Data Readouts
ACADIA showcased nine disclosed pipeline programs during its R&D Day, with five Phase II or III data readouts expected through 2027.
Key upcoming milestones include initiating a Phase II study of ACP-204 in Lewy body dementia psychosis in Q3 2025 and top-line results from the COMPASS PWS Phase III study in Q4 2025.
The company plans to start a Phase III study of trofinetide in Rett syndrome in Japan in Q3 2025 and a first-in-human study of ACP-271 before year-end.
Progress in the pipeline underscores ACADIA's strategic focus on expanding indications and leveraging novel biology, with multiple data readouts potentially transforming its market position.
Veracyte delivered approximately 25,500 Decipher tests in Q2, on track to exceed 100,000 tests annually, marking a significant milestone.
Decipher volume grew 28% year-over-year, with 13 consecutive quarters of over 25% growth, driven by strong execution and expanding clinical utility.
The metastatic prostate cancer test launch in June has generated increased physician interest, especially in high-risk NCCN patients, contributing to halo effects and future growth potential.
The company expects Decipher to maintain double-digit growth driven by market share gains, incidence growth, and expanding clinical evidence, including ongoing prospective trials and guideline updates.
Progress in Clinical Pipeline with FID-007 and FID-022
FID-007 progressing through Phase II trial in head and neck cancer, with 32 patients enrolled and data readout expected in 2026.
Fid-022 in early Phase I trial targeting solid tumors such as colon, pancreatic, ovarian, and bile duct cancers.
Projected clinical trial costs are approximately $30 million for FID-007 and $8 million for FID-022, with ongoing progress seen as promising for heavily pretreated patients.
Progress and Expectations for ARCT-032 Cystic Fibrosis Program
The company is enrolling adult CF patients in a Phase II trial with inhaled ARCT-032, targeting non-responders to CFTR modulators.
Enrollment of the second cohort at 10-milligram dose is expected to complete in early September 2025, with interim data anticipated in September.
The trial focuses on a challenging patient population with severe unmet medical needs, emphasizing safety and lung function improvements.
Regulatory discussions with the FDA are planned for the first half of 2026 to align on pivotal trial design, including adolescent and pediatric enrollment.
The company highlights the potential for inhaled mRNA therapy to be a significant breakthrough for CF non-responders, differentiating from systemic small molecule modulators.
Dosing at 280 mg over 28 days is a novel approach, supported by proprietary delivery technology and drug purification methods.
Disappointing Phase III Hyalofast Trial Results and Impact on FDA Submission Timeline
The U.S. pivotal Phase III trial for Hyalofast missed its primary endpoints, with statistical significance not achieved on co-primary measures of KOOS Pain and IKDC Function.
The trial faced challenges due to declining use of microfracture, higher dropout rates, missed visits during COVID, and reduced evaluable sample size.
Despite the miss on primary endpoints, secondary endpoints showed statistical significance, and international data with positive 15-year outcomes support the product's value.
The company plans to submit the third and final PMA module in the second half of 2025, extending the review timeline to 2027 to ensure thorough review and dialogue with the FDA.
Seres has advanced preparation for the next stage of SER-155 development, including a Phase II protocol submission to the FDA.
The Phase Ib study showed a 77% relative risk reduction in bloodstream infections in allo-HSCT patients, supporting further development.
The upcoming Phase II study is designed to enroll approximately 248 patients with an adaptive design and interim analysis, with results expected within 12 months of initiation.
Positive interactions with the FDA and breakthrough therapy designation facilitate the study design and potential approval pathway.
The company aims to use interim data to inform next steps, including potential engagement with the FDA for a registrational study.
Dafinchi
